Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 989 across all filing types
Latest filing 2021-07-01 Share Issue/Capital Cha…
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
Application for quotation of securities - TLX 6 pages 28.0KB
Share Issue/Capital Change Classification · 100% confidence The document is an application for quotation of securities on the ASX, detailing the issuance and conversion of options into ordinary fully paid shares. It includes specifics about the number of securities, issue dates, prices, and the resulting issued capital. This is a formal announcement related to the issuance and quotation of new shares, which fits the category of Share Issue/Capital Change filings. The document is not a financial report, earnings release, or management discussion, but rather a regulatory announcement about capital changes.
2021-07-01 English
1st patient dosed in TLX250-CDx study in Bladder Cancer 2 pages 211.5KB
Regulatory Filings Classification · 90% confidence The document is a press release announcing the dosing of the first patient in a clinical study of TLX250-CDx in bladder cancer by Telix Pharmaceuticals Limited. It provides detailed information about the study, the drug candidate, and the company's background. There are no financial statements, earnings data, or regulatory filings such as annual or interim reports. The content focuses on clinical trial progress and company product development updates, which aligns with a Capital/Financing Update or general corporate announcement. However, since it is specifically about a clinical study milestone and not about fundraising or capital structure changes, it does not fit the Capital/Financing Update category. It is also not a regulatory filing or report publication announcement. Given the nature of the announcement as a corporate update on clinical development, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous corporate announcements that do not fit other categories.
2021-06-22 English
TLX101 for Glioblastoma Therapy - Clinical Trial Update 2 pages 201.1KB
Regulatory Filings Classification · 95% confidence The document is a clinical trial update announcement from Telix Pharmaceuticals Limited regarding the IPAX-1 study for TLX101 in glioblastoma therapy. It provides information about patient recruitment status, interim safety and efficacy analysis, and future study plans. There are no financial statements, regulatory filings, or detailed financial data. The document is relatively short (4616 characters) and serves as an update on clinical trial progress rather than a financial or regulatory report. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is an operational update related to clinical trial progress, which is best categorized under Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2021-06-20 English
Update on FDA New Drug Application Review for Illuccix 2 pages 201.0KB
Regulatory Filings Classification · 95% confidence The document is an announcement from Telix Pharmaceuticals Limited regarding an update on the FDA New Drug Application (NDA) review for their product Illuccix. It discusses the status of regulatory review meetings and the company's expectations for approval and launch. The document is relatively short (4121 characters) and does not contain any financial statements, detailed financial data, or comprehensive report content. It is primarily a regulatory update and corporate announcement about the progress of a drug approval process. There is no indication that this is a full annual report, interim report, earnings release, or any other detailed financial or governance report. It also does not fit into categories like M&A, capital updates, or voting results. Given the nature and length, this fits best as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-06-16 English
Telix and ATS $1.56M Eurostars Grant for Alpha Therapy 2 pages 208.4KB
Capital/Financing Update Classification · 95% confidence The document is a press release announcing that Telix Pharmaceuticals and ATS have been awarded a research grant for a specific project related to alpha therapy. It discusses the grant amount, project scope, and collaboration details. There is no financial data, no regulatory filing references, no meeting materials, no voting results, no management changes, no earnings or interim report data, and no audit or legal proceedings information. The document is an update on a financing/grant award related to research funding, which fits best under Capital/Financing Update (CAP). The document length is 6217 characters, which is sufficient for a substantive announcement rather than a brief notice. Therefore, the classification is CAP with high confidence.
2021-06-06 English
US Co-Promotion with EZAG for Prostate Cancer Imaging 2 pages 205.4KB
Capital/Financing Update Classification · 90% confidence The document is a press release announcing a co-promotion agreement between Telix Pharmaceuticals Limited and Eckert & Ziegler for prostate cancer imaging products. It discusses the terms of the agreement, the companies involved, and regulatory statuses of the products, but does not contain financial statements, management discussion, or detailed financial data. It is not an earnings release, annual report, or any form of financial report. It is also not a regulatory filing or certification. The content is primarily an update on a business collaboration and product marketing strategy, which fits best under Capital/Financing Update (CAP) as it relates to business development and commercial agreements impacting the company's capital and market activities.
2021-06-02 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.